Stop Tissue Loss in 10 Minutes: Clinician SOP for Filler Complications

If you suspect vascular compromise after a filler injection, stop injecting immediately, check capillary refill time and pain, and treat accordingly. Give hyaluronidase promptly if hyaluronic acid (HA) is the likely filler, and arrange urgent ophthalmology or emergency department referral for any visual symptoms. Delay is the single biggest driver of poor outcomes in vascular occlusion.

TL;DR:

• Immediate cessation of injection and assessment of capillary refill time are critical; CRT longer than 2-3 seconds indicates vascular occlusion.
• Hyaluronidase must be administered promptly into the affected area in high doses, with reassessment every 10 to 15 minutes until perfusion improves.
• Document all interventions with precise timing, photographs, CRT measurements, and patient symptoms to ensure clear records and proper reporting.
• For visual loss, stop injecting, attempt ocular massage, give aspirin, and transfer quickly to specialist ophthalmology services with hyaluronidase on hand.
• Preventative measures like using microboluses, slow injection, and knowledge of vascular anatomy are vital to reducing filler complication risks.

Table of Contents

• Filler complications management: what to do in the first minutes
• What is the emergency checklist for vascular occlusion?
• How do you recognise vascular occlusion versus normal bruising?
• When and how should you use hyaluronidase?
• What should you do for suspected filler-related vision loss?
• How do you manage delayed nodules, infection and inflammation?
• What injection techniques reduce filler complication risk?
• What should you document and report after a filler complication?
• How does a clinic-level protocol work in practice?
• A clinician's perspective on preparedness
• How clinics can support clinicians managing filler risk
• Sources
• FAQ

Filler complications management: what to do in the first minutes

Effective filler complications management starts with a decision, not a diagnosis. The moment you see disproportionate pain, mottled or blanched skin, or a delay in capillary refill, you treat it as vascular occlusion (VO) until proven otherwise. Waiting for certainty costs tissue.

VO is rare, occurring in roughly 0.001% of cosmetic filler injections, but rarity is exactly why so many practitioners freeze when it happens. You will likely see it only a handful of times across a career, which means your response has to be rehearsed rather than improvised. The Aesthetic Complications Expert (ACE) Group and peer-reviewed consensus statements from groups including Urdiales-Gálvez and colleagues converge on the same core sequence: stop, assess, treat, escalate. This article builds that sequence into a working protocol you can print, rehearse, and adapt for your own clinic.

What is the emergency checklist for vascular occlusion?

A vascular event demands a fixed order of operations, not a checklist you interpret under pressure. Work through these steps in sequence.

1. Stop injecting immediately. Withdraw the needle or cannula and do not attempt to "finish the area."
2. Assess capillary refill time (CRT). Press the skin, release, and time the return of colour. Anything beyond 2 to 3 seconds is abnormal and treat as an occlusion.
3. Photograph and time-stamp. Capture the blanching, dusky discolouration, or livedo pattern with a timestamp, before and after each intervention.
4. Apply warmth and gentle massage. Heat and firm massage to the affected area can help re-establish flow while you prepare hyaluronidase.
5. Give hyaluronidase without delay if HA filler is implicated. High-dose pulsed dosing into the affected territory is the mainstay treatment and should not wait for imaging or specialist confirmation.
6. Administer 300 mg aspirin orally, stat, if there is no contraindication, to reduce clot propagation.
7. Reassess CRT and pain every 10 to 15 minutes, redosing hyaluronidase as needed until perfusion normalises.
8. Escalate to ED or ophthalmology if there is no improvement, or immediately if any visual symptoms appear.

Additional points worth keeping on your printed protocol:

• Ocular massage and topical timolol are appropriate first responses if there is any suspicion of ocular involvement, alongside the aspirin dose above.
• Keep at least 1,500 IU of hyaluronidase on-site, and know your reconstitution ratio before you ever need it under pressure.
• If transfer is required, accompany the patient where possible and bring hyaluronidase with you.
• Never send a patient away with "watch and wait" advice if CRT is delayed or pain is disproportionate.

Pro Tip: Laminate your emergency protocol and pin it inside the treatment room, not in a folder in reception. In an occlusion, nobody has time to search for a document.

How do you recognise vascular occlusion versus normal bruising?

The defining triad is pain out of proportion to the injection, visible blanching or dusky discolouration, and a delayed CRT. Any one sign alone can be misleading; together, they are close to diagnostic.

CRT is your most objective bedside tool. Press firmly on the skin for a few seconds, release, and count how long colour takes to return. A CRT beyond 2 to 3 seconds in the treated area, compared with an unaffected control site, is a red flag that should trigger the emergency checklist above rather than a "wait and see" approach.

Livedo reticularis, a mottled, lace-like purplish pattern, signals reduced blood flow through the small vessels and differs from a simple bruise in both appearance and behaviour. Bruising is typically flat, uniform in colour progression, and confined to the injection site. Livedo spreads in a net-like pattern that can extend beyond where you injected, and it tends to worsen rather than settle over the following hour. Document both with photographs at set intervals; the progression pattern often tells you more than a single image.

Key figure: Vascular occlusion occurs in an estimated 1 in 100,000 filler treatments, which is precisely why most practitioners have never managed a real case and need a rehearsed protocol rather than memory to fall back on.

Local anaesthetic, particularly formulations containing adrenaline, can mask or distort early signs by causing vasoconstriction and numbing the pain that would otherwise alert you. If you have used an adrenaline-containing anaesthetic, extend your observation window and check CRT more frequently, because the earliest warning sign, patient-reported pain, may simply not be there yet.

When and how should you use hyaluronidase?

Hyaluronidase is the enzyme that breaks down hyaluronic acid, and it is the gold-standard treatment for HA filler-related vascular occlusion. It has two distinct clinical uses that call for different dosing philosophies: emergency dissolution during a vascular event, and elective correction of a misplaced or overcorrected filler.

Indications for use include:

• Suspected or confirmed vascular occlusion following HA filler injection.
• Impending necrosis, indicated by progressive blanching, dusky discolouration, or worsening pain.
• Visual disturbance following filler injection near the glabella, nose, or forehead, alongside emergency referral.
• Elective removal of misplaced, excessive, or lumpy HA filler once any emergency has resolved.

When to withhold or delay it:

• Active untreated infection at the injection site, where hyaluronidase should generally follow, not precede, antibiotic cover.
• Known hypersensitivity to hyaluronidase itself, though this is rare and should not delay emergency treatment in a genuine vascular event.

Dosing principles for vascular occlusion

The ACE Group and international consensus guidance both favour a high-dose pulsed protocol over small, cautious doses. In practice, this means flooding the affected vascular territory (the "angiosome") with hyaluronidase rather than injecting a token amount and waiting to see what happens. Reassess CRT and skin colour every 10 to 15 minutes, and repeat dosing if perfusion has not visibly improved. This pattern of repeated administration, guided by clinical response rather than a fixed total dose, is what distinguishes emergency use from routine correction work.

For non-emergency dissolution of misplaced or lumpy filler, many practitioners work from a practical guide of roughly 20 to 30 units per 0.1ml of HA product, titrated to the visible or palpable response. This figure is a working convention rather than a formally validated dosing standard, so always prioritise your local clinic protocol and the cited consensus guidelines above it when a genuine vascular event is in play.

Reconstitution matters as much as the dose itself. Dilute according to your product's licensed instructions and check the concentration on the vial before every use, particularly if your clinic stocks more than one hyaluronidase brand. Errors here tend to happen under pressure, which is exactly when you cannot afford them.

Pro Tip: Keep a single pre-calculated dosing card next to your hyaluronidase stock, showing exact reconstitution volumes for your specific product. Recalculating dilutions from memory during an active occlusion invites errors nobody has time to catch.

Ultrasound-guided injection is an increasingly useful adjunct, particularly for deeper or more complex occlusions where the exact vessel involved is unclear. Mapping the vascular anatomy before redosing improves the precision of enzyme delivery and can shorten the time to resolution in cases that do not respond to blind treatment. If your clinic has access to portable ultrasound and trained staff, build it into your escalation pathway rather than treating it as a luxury.

Always observe patients for a minimum of 60 minutes after hyaluronidase administration. The enzyme can transiently worsen inflammatory appearance as it breaks down HA, which can look alarming if you have not warned the patient and your team to expect it. Schedule a follow-up review within 24 to 48 hours regardless of how settled the area looks at discharge.

What should you do for suspected filler-related vision loss?

Sudden visual disturbance following filler injection, particularly around the glabella, nasal dorsum, or forehead, is a genuine ophthalmic emergency. Community measures buy time; they do not replace hospital care.

1. Stop injecting and reassure the patient calmly while you begin the sequence below.
2. Attempt ocular massage, applying firm intermittent pressure to the globe to try to dislodge or disperse the embolus.
3. Apply topical timolol if available, which may help reduce intraocular pressure.
4. Administer a single 300 mg dose of aspirin if there is no contraindication, to limit clot propagation.
5. Consider rebreathing into a paper bag briefly, as the resulting mild hypercapnia may promote retinal vasodilation.
6. Call ahead to the nearest ophthalmology or stroke service while arranging immediate transfer, and bring hyaluronidase with you to hospital.

None of these measures reliably restores vision on their own. Published management recommendations frame ocular massage, timolol, and aspirin as bridging actions while the patient is transferred, not as definitive treatment, because retinal and ophthalmic artery occlusion generally require specialist intervention within a very narrow window.

Guidance consistently recommends having at least 7,500 IU of hyaluronidase available to bring with the patient to hospital, since retrobulbar or intra-arterial hyaluronidase administration is sometimes attempted by specialist teams on arrival.

What you say at handover matters as much as what you do beforehand. Give the receiving team the injection product used, the time of onset, every intervention attempted with its timing, and the patient's current visual symptoms in their own words. A confused or incomplete handover wastes minutes that the patient cannot afford to lose.

How do you manage delayed nodules, infection and inflammation?

Not every lump or reaction is an emergency, but delayed complications still need a structured differential rather than a reflexive antibiotic prescription. Nodules appearing days to weeks after treatment fall broadly into inflammatory, infective, or biofilm-related categories, and the management pathway differs meaningfully between them.

Start with a careful history and examination. A nodule that is warm, tender, fluctuant, or associated with systemic symptoms points towards infection and warrants a swab and culture before you commit to a treatment path. A firm, non-tender nodule appearing weeks later, sometimes triggered by an unrelated illness or vaccination, is more typical of a delayed inflammatory reaction or granuloma. Where diagnosis remains unclear, biopsy should be considered rather than treating blind.

A practical management pathway:

• Start with conservative measures for mild, non-infective nodules: warm compress, gentle massage, and review in one to two weeks.
• Begin empirical broad-spectrum antibiotics promptly if infection is suspected, following your local antimicrobial guidance, before escalating.
• Reserve intralesional steroids for confirmed inflammatory or granulomatous reactions once infection has been excluded, since steroids in an infected nodule can worsen the picture.
• Use hyaluronidase to dissolve the filler itself when the nodule is HA-based and conservative measures fail, once any infection is controlled.
• Refer to dermatology if nodules persist beyond several weeks despite treatment, or recur repeatedly.

Set a follow-up review at one week for any treated nodule, and escalate sooner if pain increases, the area spreads, or systemic symptoms such as fever develop. A nodule that is improving slowly is manageable in clinic; one that is worsening under treatment needs specialist input, not a repeat of the same plan.

What injection techniques reduce filler complication risk?

Prevention is cheaper than any emergency protocol, and most of it comes down to technique discipline rather than equipment. Build these habits into every injection, not just the ones in visibly risky zones.

1. Use microboluses. Deposit small aliquots rather than large volumes in a single pass, which limits the damage if you are inadvertently intravascular.
2. Limit volume per pass. Cap how much product you deliver before repositioning the needle or cannula, rather than emptying the syringe in one movement.
3. Inject slowly with low plunger pressure. High-pressure boluses are more likely to force product into a vessel and to push it further along the vascular tree if an occlusion begins.
4. Aspirate before injecting where your technique and product viscosity allow it, understanding that a negative aspirate does not guarantee safety.
5. Use a blunt cannula in recognised high-risk zones, including the glabella, nasolabial folds, and nasal region, where the vascular anatomy is less forgiving of needle-based technique.
6. Know the anatomy of the angiosome you are treating before you pick up the syringe, not while you are troubleshooting a complication.

Pre-procedure assessment matters just as much as technique on the day. Take a full medical history, ask specifically about previous filler treatments and any prior complications, and screen for vascular risk factors such as smoking or connective tissue disease. Document consent thoroughly, including the discussion of rare but serious risks, before every treatment, not just the first one. Our dermal filler safety guidance sets out the pre-treatment checks worth building into your own patient intake process.

Clinic readiness is the final layer. Every treatment room should have an emergency kit containing hyaluronidase, aspirin, topical timolol, and a printed protocol with your nearest ED name and postcode already filled in. Run a staff drill at least twice a year so that everyone, not just the injector, knows their role if an occlusion happens on a day you are not in the building.

Pro Tip: Rehearse your vascular occlusion protocol with a stopwatch running. Most clinics discover their "ready" emergency kit actually takes several minutes to locate and assemble under real time pressure.

What should you document and report after a filler complication?

Documentation during a live emergency needs to be fast, specific, and time-stamped, because memory reconstructed after the event is rarely accurate and rarely defensible.

• Record the exact time of symptom onset, and the time of every subsequent intervention, including each hyaluronidase dose and its volume.
• Photograph the affected area at each reassessment, with a visible timestamp.
• Note CRT readings at each check, not just a final "improved" or "unchanged" summary.
• Log the patient's own description of pain and any visual symptoms, in their words where possible.
• Record who was present, who administered each treatment, and when transfer to ED was requested and completed.

Consent taken before the original treatment should already have covered the rare but serious risk of vision loss, alongside more common risks, and should include explicit permission to share records with the patient's GP or a specialist if a complication arises. Retrofitting this conversation after a complication has occurred is far weaker, medicolegally, than having it documented beforehand.

Report every significant complication through the appropriate channels: the MHRA Yellow Card scheme for adverse event reporting, the filler manufacturer directly, and your professional indemnity insurer, who will usually want early notification rather than a call after the fact. These three reporting steps protect the wider patient population as well as your own position.

How does a clinic-level protocol work in practice?

A written guideline only helps if your team can execute it inside minutes, which is why some clinics build their own working "10 minute protocol" around the same core sequence covered above: stop, assess CRT, treat, and escalate, compressed into a rehearsed sequence rather than a reference document nobody opens under pressure.

The reproducible elements worth borrowing for any clinic are straightforward. A single-page checklist lives in every treatment room, not a shared drive. Hyaluronidase stock and expiry dates should be checked regularly to avoid discovering emptiness during an emergency. Every member of staff, not just injectors, should know the nearest ED and the exact handover information to give.

A practical documentation template should capture, at minimum, time of onset, CRT readings at each check, every intervention with dose and timing, and photographs at set intervals. Our own 10 minute protocol guide for UK clinicians sets out a downloadable version of this template alongside the emergency kit checklist we use ourselves, and our filler aftercare guidance covers the written instructions worth giving patients once any acute issue has resolved.

A clinician's perspective on preparedness

Most clinics believe they are prepared until the first real occlusion arrives, and that gap between believing and being prepared is where patients get hurt. A protocol read once during induction training is not the same as a protocol rehearsed with a stopwatch, twice a year, until the whole team can move without thinking.

The technical steps matter, but how you speak to a frightened patient matters just as much and gets far less attention in the literature. Explain what you are doing and why, in plain language, as you do it, rather than working in silence while anxiety builds. Document that conversation too; a patient who felt informed throughout a frightening event is far less likely to feel let down afterwards, regardless of the outcome.

If your clinic does one thing this week, it should be locating your hyaluronidase stock, checking its expiry, and timing how long it actually takes your team to assemble the emergency kit under pressure.

— Ms Sandra Petraskaite

How clinics can support clinicians managing filler risk

Reading a protocol is not the same as being able to run one under pressure, which is where structured training closes the gap that most clinics only discover during a real event. Accredited training courses and emergency protocol workshops built specifically around vascular occlusion recognition, hyaluronidase dosing, and team drills are valuable for practitioners who want their whole clinic rehearsed, not just their reference folder updated.

Alongside training, downloadable clinic templates covering emergency kit checklists and documentation forms are available through our treatments and services pages, and clinicians looking for a fuller framework can review our signature treatment programmes for how protocol thinking extends into day-to-day patient care. If you want specialist support setting up or auditing your own emergency pathway, get in touch with the Nexgen Clinic team through our main site to book a training slot or request a clinic consultancy visit.

This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.

Sources

• Management of a vascular occlusion associated with cosmetic injections
• Management recommendations for filler-related ocular complications
• ACE Group management of vascular occlusion guideline

FAQ

What are the high-risk areas for filler complications?

The glabella, nasal dorsum, nasolabial folds, and forehead carry the highest vascular occlusion risk because of dense, less variable arterial networks feeding the ophthalmic circulation.

What is forbidden after fillers?

Patients should avoid vigorous exercise, alcohol, extreme heat, and facial massage in the first 24 to 48 hours, and should never ignore disproportionate pain, spreading discolouration, or visual changes, which need same-day clinical review.

What are the signs of bad fillers?

Disproportionate pain, skin blanching or dusky discolouration, a delayed capillary refill time beyond 2 to 3 seconds, and any visual disturbance are the key warning signs requiring immediate assessment.

What are the common complications of dermal fillers?

Bruising and swelling are the most frequent, minor effects, while delayed nodules, infection, and inflammatory reactions occur less often and vascular occlusion remains rare, at roughly 1 in 100,000 treatments.

How quickly should hyaluronidase be given for suspected vascular occlusion?

Hyaluronidase should be given as soon as vascular occlusion is suspected, without waiting for imaging or specialist confirmation, since early high-dose pulsed dosing is directly linked to better tissue outcomes.

Recommended

• 10 Minute Protocol for UK Clinicians Managing Filler Complications
• Filler aftercare: your first 48 hours and beyond
• Clinician Led Filler Migration: HA Often Dissolves Within 24–4